Modakafusp Alfa Demonstrates Activity in Rel/Ref Multiple Myeloma – Oncology Nurse Advisor
Both dose levels of modakafusp alfa “resulted in good response rates with similar safety profiles,” according to researchers.
Related Articles
Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma
This nonrandomized clinical trial in pediatric relapsed classic Hodgkin lymphoma tested fludeoxyglucose-18 positron emission tomography scans to identify patients in whom transplant-free salvage therapy would…
Subcutaneous Isatuximab Combo Hits Primary End Points in Phase 3 Trial
The phase 3 IRAKLIA trial of subcutaneous isatuximab met its co-primary end points in multiple myeloma.
3 QUESTIONS ON . . . ‘Spillover’ Savings for the Oncology… : Oncology Times
An abstract is unavailable.
Program: Tuesday, February 25
tuesday, february 25 *-Short talk from proffered abstract CONTINENTAL BREAKFAST 7-8 a.m. Major Symposia 4-5 8-9:30 a.m. Major Symposium 4: Neoadjuvant Immunotherapy Session Chair: Christian…
Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC
Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.
‘All for one’: City of Hope oncologist focuses on patients after evacuating fires
Ravi Salgia, MD, PhD, and his family were watching coverage of the Los Angeles County fires on their television around 6 p.m. Jan. 7 when…
Understanding the Mechanism and Sensitivity of BCL-2 Inhibitors
John Seymour, MBBS, FRACP, PhD, explains the mechanism of action of BCL-2 inhibitors like venetoclax.
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults
This nonrandomized clinical trial evaluates a risk-stratified, response-adapted, transplant-free approach for treatment of children, adolescents, and young adults with low-risk relapsed classic Hodgkin lymphoma with…
Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer
The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.
Allo-HSCT Consolidation Appears Beneficial for Older AML Patients
A phase 3 trial confirms “the potent anti-leukemic effect” of consolidation with allogeneic transplant in older patients with acute myeloid leukemia, according to researchers.
